Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
600196
Kedudukan dalam Saham
#2197
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical... Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
Harga Saham
$3.40
Modal Pasaran
$9.07B
Perubahan (1 hari)
-1.61%
Perubahan (1 tahun)
-16.08%
Negara
CN
Perdagangan Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196)
Kategori
Healthcare
Nisbah P/E bagi Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Shanghai Fosun Pharmaceutical (Group) Co., Ltd., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Shanghai Fosun Pharmaceutical (Group) Co., Ltd. dari 2001 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2025 | 20.86 | -12.71% |
| 2024 | 23.89 | -14.46% |
| 2023 | 27.93 | 13.42% |
| 2022 | 24.63 | -7.15% |
| 2021 | 26.52 | -29.79% |
| 2020 | 37.78 | 84.06% |
| 2019 | 20.52 | 2.24% |
| 2018 | 20.08 | -42.70% |
| 2017 | 35.03 | 83.27% |
| 2016 | 19.12 | -12.93% |
| 2015 | 21.95 | -4.19% |
| 2014 | 22.91 | -17.00% |
| 2013 | 27.61 | 111.33% |
| 2012 | 13.06 | -6.81% |
| 2011 | 14.02 | -52.13% |
| 2010 | 29.28 | 202.92% |
| 2009 | 9.67 | -48.95% |
| 2008 | 18.94 | -37.97% |
| 2007 | 30.53 | 48.06% |
| 2006 | 20.62 | -23.25% |
| 2005 | 26.87 | 31.61% |
| 2004 | 20.41 | 20.97% |
| 2003 | 16.88 | -39.62% |
| 2002 | 27.95 | -26.73% |
| 2001 | 38.15 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | - |
IN
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.